Reproduction permitted for personal use only. For reprints and reprint permission, contact email@example.com.
- NimbleGen Systems
scientist Thomas Albert will lead a federally funded investigation into new and innovative uses for microarray technology in DNA sequence analysis, the company announced.
Albert, director of advanced research for NimbleGen, will be the lead investigator on a two-year, $415,000 grant award that is part of the federal government's $3.4 million Cancer Genome Atlas pilot project.
His work will expand on earlier NimbleGen research into new uses of microarray technology for the selection of genomic regions for DNA sequence analysis. The company believes targeted sequencing can lead to the development of advanced analytical capabilities that have applications in research and healthcare.
The Cancer Genome Atlas Project is being conducted by the National Cancer Institute
and the National Human Genome Research Institute
. Both organizations are part of the National Institutes of Health
NimbleGen to discontinue IPO after Roche's $272.5 million acquisition
Tom Still: Wisconsin IPOs are a harbinger of growing tech economy
IPO-bound NimbleGen traveling in fast company
Madison biotech NimbleGen files for IPO; one of states' best-funded firms
Genomics researcher Hood joins NimbleGen board